Jan 8 (Reuters) - Compass Therapeutics Inc. CMPX.O:
COMPASS THERAPEUTICS PROVIDES CORPORATE UPDATE AND ANNOUNCES ADVANCEMENT OF A NEW DRUG CANDIDATE
COMPASS THERAPEUTICS INC. - TOP-LINE PHASE 2/3 DATA FOR TOVECIMIG EXPECTED END OF Q1 2025
COMPASS THERAPEUTICS: ESTIMATES $127 MILLION IN CASH & MARKETABLE SECURITIES AT YE 2024, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO Q1 2027
COMPASS THERAPEUTICS INC. - TWO PHASE 2 BIOMARKER TRIALS EXPECTED TO INITIATE MID-2025
COMPASS THERAPEUTICS INC.: EXPECT TO SUBMIT AN IND BY END OF 2025 FOR CTX-10726
Source text: nGNX6z5Lq4
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.